Impact of Butyricicoccus Pullicaecorum in Healthy Subjects

A Placebo-controlled Cross-over Randomized Study to Investigate the Impact of Butyricicoccus Pullicaecorum in Healthy Human Volunteers

During this project the safety, tolerability and effect on gut microbiota of oral administration of Butyricicoccus pullicaecorum was investigated in healthy human volunteers by a placebo-controlled cross-over randomized study.

Intervention periods were 4 weeks, with daily intake of 1 capsule. Wash-out periods were 3 weeks.

Inclusion Criteria:

• BMI between 18 and 28 kg/m²
• Good general health
• Regular eating pattern (3 meals/day on at least 5 days/week)

Exclusion Criteria:

• Chronic gastrointestinal disease (Crohn's disease, ulcerative colitis, irritable bowel syndrome, chronic constipation or chronic diarrhea)
• Surgery of the gastrointestinal tract (except for an appendectomy)
• Use of antibiotics during the month preceding the study
• Use of medication or dietary supplements influencing gut transit or intestinal microbiota during the month preceding the study. Examples of such medication/dietary supplements are antispasmodics (e.g. buscopan), antidiarrheal medication (e.g. imodium), probiotic medication (e.g. lacteol, enterol)
• Intake of pre- or probiotics during the study or during the month preceding the study
• Being on a weight-loss diet during the study or during the month preceding the study
• Extreme dietary habits (e.g. vegan, Atkins diet, Montignac diet)
• Females who are pregnant, lactating or planning to become pregnant during the study period